Todd Trattner

Todd’s experience includes advising:

Royalty Finance and Other Financings / Offerings 

• Royalty Pharma on acquiring royalty interests in:
  • Amgen’s Imdelltra from BeOne Medicines for up to US$950 million*
  • Sanofi’s frexalimab from ImmuNext for US$525 million*
  • Karuna Therapeutics’ KarXT from Puretech Health for up to US$500 million*
  • Syndax’s Niktimvo for US$350 million* 
  • Teva’s olanzapine for up to US$125 million, as well as a clinical funding arrangement*
  • Roche’s Gavreto from Blueprint Medicines for up to US$340 million*
  • Alnylam’s Oxlumo from Dicerna Pharmaceuticals for up to US$240 million*
• RTW on acquiring synthetic royalties in:
  • Aquestive Therapeutics’ Anaphylm for US$75 million, with a concurrent stock acquisition as the lead investor in the company's US$85 million offering*
  • Allurion’s gastric balloon for up to US$115 million, with a concurrent PIPE investment and purchase of a convertible note*
  • Avadel’s Lumryz for up to US$75 million*
  • Milestone Pharmaceuticals’ etripamil, with a concurrent purchase of convertible notes, for US$125 million*
  • Urogen’s urology drug for US$75 million*
• Healthcare Royalty Partners on acquiring royalty interests in:
  • Bayer’s Beyonttra from BridgeBio Pharma for US$300 million*
  • Astra Zeneca’s Movantik and Takeda’s Adynovate from Nektar Therapeutics for US$150 million*
  • Pfizer’s Ruxience from Aptevo Therapeutics for up to US$67.5 million*
  • Zynlonta from ADC Therapeutics for US$325 million*
• Blue Owl Capital on acquiring royalty interests in Bayer’s Beyontrra from BridgeBio Pharma for US$300 million and Teva’s Bendeka from Eagle Pharmaceuticals for US$69 million*
• XOMA Royalty on multiple traditional and synthetic royalty financings, including acquiring a royalty interest in Takeda’s mezagitamab from BioInvent International and a royalty-backed loan from Blue Owl for up to US$140 million*
• TPG Capital on its US$300 million Series A financing of Allogene Therapeutics, as lead investor, and related JV with Pfizer*
• Uber in its US$1 billion equity financing and restructuring of its self-driving car business with Toyota, Sofbank, and Denso*
• BVF Partners on:
  • A JV with Aslan Pharmaceuticals and Series A financing with Vellera Therapeutics*
  • A royalty-backed financing of Infinity Pharmaceuticals for US$20 million*
  • A private placement with Eledon Pharmaceuticals for US$108 million, as lead investor*
  • Acquiring royalty interests in Avanir Pharmaceuticals’ AVP-786 from Concert Pharmaceuticals*
• DRI on acquiring royalty interests in elacestrant from Radius Health for up to US$140 million and Janssen’s Edurant and Complera from AstraZeneca*
• UCLA on selling multiple royalty interests to Royalty Pharma, including a royalty interest in Xtandi for US$1.15 billion and a royalty interest in Erleada*
• Esperion Therapeutics on selling royalty interests in Daiichi Sankyo’s bempedoic acid products to OMERS Life Sciences for over US$300 million*
• Arrowhead Pharmaceuticals on selling royalty interests in Olpasiran to Royalty Pharma for up to US$410 million and its strategic financing agreement with Sixth Street for US$500 million*
• Ultragenyx on selling its royalty rights in Crysvita to Royalty Pharma for US$320 million and to OMERS Capital Markets for US$500 million*
• Sutro Biopharma on selling royalty interests in Vaxcyte’s products, including VAX-24, to Blackstone Life Sciences for up to US$390 million*
• Atara Biotherapeutics on selling royalty interests to Healthcare Royalty Partners for US$31 million*
• RXi Pharmaceuticals on its US$15 million follow-on offering*
• California Water Service Group on its US$150 million ATM offering*
• BioCryst Pharmaceuticals on multiple synthetic royalty sales to Royalty Pharma and OMERS Capital Markets, as well as concurrent stock sales and term loans, for total proceeds of US$675 million*
• Spero Therapeutics on selling synthetic royalties for up to US$125 million*
• CTI BioPharma on its synthetic royalty of pacritinib, with a concurrent term loan, for up to US$135 million*
• Cogent Biosciences on its debt financing facility of up to US$400 million with credit funds managed by SLR Capital Partners*
• Morgan Stanley’s North Haven Tactical Value Fund on a term loan facility with FibroGen of up to US$150 million*
• Immedica Pharma on royalty and IP acquisitions with Ovid Therapeutics*
• Ecor1 Capital on its private placement investment in NephroGenex*
• An investor on Renova Therapeutics’ Series A financing*
• PDL Biopharma on:
  • Selling royalty interests for Kybella, Zalviso, and Coflex to SWK Funding*
  • Multiple royalty stream acquisitions totaling over US$385 million from the University of Michigan, Depomed, Visgliosi Brothers, and AcelRX Pharmaceuticals*

Licensing, Strategic Alliances, and M&A

• Arrowhead Pharmaceuticals on:
  • A global collaboration with Sarepta Therapeutics to develop and commercialize Arrowhead’s RNA interference therapeutics in rare diseases for up to US$10.1 billion plus royalties, with an upfront and near term payments of US$1.4 billion*
  • An exclusive license agreement with GlaxoSmithKline to develop and commercialize ARO-HSD for up to US$1 billion plus royalties, with a US$120 million upfront*
  • A joint venture and license with Vivo Capital to develop and commercialize certain of Arrowhead’s RNA interference therapeutics in Greater China*
• KKR on investing in Biosynth Carbosynth and Biosynth Carbosynth's acquisition of vivitide*
• Royalty Pharma on merging with ImmuNext*
• Sage Therapeutics on a global collaboration with Biogen to develop and commercialize zuranolone (SAGE-217) and SAGE-324, valued in excess of US$1.5 billion*
• Merck on a global collaboration to develop and commercialize AAV gene therapies*
• XOMA Royalty on its acquisition of HilleVax and its merger with Pulmokine*
• Novartis Pharmaceuticals on multiple settlement and license agreements*
• Uber on multiple strategic licenses, IP transfers, M&A, commercial agreements, and corporate restructuring*
• Alcon on selling and licensing rights to develop and commercialize eye drop products in China to Ocumension Therapeutics in exchange for 16.7% of Ocumension’s equity*
• Medincell on a global collaboration with AbbVie to develop and commercialize therapeutic products using Medincell’s injectable technology*
• CSL Seqirus on multiple settlement and license agreements*
• SomaLogic on acquiring Palamedrix*
• US WorldMeds on its acquisition of Adaptimmune Therapeutics’s cell therapy business*
• Agex Therapeutics on merging with Serina Therapeutics*
• Marvell Technology on selling its wi-fi connectivity business to NXP Semiconductors for US$1.76 billion*
• InnoCare Pharma on a collaboration with Biogen for orelabrutinib (a BTK inhibitor) for up to US$937 million plus royalties, with a US$125 million upfront, and an in-license with Incyte for rights to tafasitamab (a CD19 targeting monoclonal antibody) in Greater China, for up to US$118 million, with a US$35 million upfront*
• Selecta Biosciences on:
  • An exclusive license with SOBI to develop and commercialize SEL-212, for up to US$730 million, with a US$100 million upfront*
  • A strategic license agreement with Takeda to use Selecta’s ImmTOR platform to develop gene therapies, for up to US$1.12 billion*
  • A strategic collaboration with AskBio BioPharmaceutical to develop, manufacture, and commercialize targeted therapeutics for AAV gene therapies*
  • A license and option with Sarepta Therapeutics to develop and commercialize Selecta’s ImmTOR™ platform with Sarepta’s AAV gene therapy*
• Fairmont Funds on several strategic transactions for its portfolio companies*
• LivaNova on an exclusive license from an academic medical center to develop, manufacture, and commercialize a cannula device*
• Daniel Elliott on acquiring Berg Health, as lead investor of BPGbio*
• Clorox on a strategic collaboration with a sprayer manufacturer*
• SNH Capital Partners on acquiring Universal Background Screening*
• Avillion on a license agreement with AstraZeneca*
• United Therapeutics on acquiring SteadyMed*
• Theseus Pharmaceuticals on merging with Concentra Biosciences*
• Phio Pharmaceuticals (formerly RXi) on acquiring MirImmune and its exclusive license with Thera Neuropharma of its sd-rxRNA platform to develop therapeutics for neurodegenerative diseases*
• Berkeley Lights on its strategic collaboration with Thermo Fisher Scientific to accelerate and improve the development and manufacturing of stable AAV (Adeno-Associated Viral) and LV (Lentiviral) vector producer cell lines*
• Atara Biotherapeutics on selling its T-cell operations and manufacturing facility to Fujifilm Holdings for a US$100 million upfront*
• Assertio Therapeutics on:
  • Merging with Zyla Life Sciences*
  • Selling its Nucynta business to Collegium Pharmaceutical for US$375 million*
  • A strategic collaboration valued at a minimum of US$550 million*
• California Water Service Group on a contested tender offer of US$1.9 billion to acquire San Jose Water*
• Matson Navigation on its unsolicited purchase of Horizon Lines for US$469 million and carve-out of Horizon Lines’ Hawaii business for US$141.5 million, and its acquisition of Span Alaska Transportation, LLC for US$197.6 million*
• Macquarie Infrastructure on purchasing Maher Terminals from Deutsche Bank*
• Progenity on selling Avero Diagnostics*
• Alvogen on an exclusive license agreement with NRx Pharmaceuticals to develop and commercialize NRX-101 (NRx’s D-cycloserine and Lurasidone combination product)*
• Roivant on its exclusive license from Eisai for global rights to exploit the investigational anticancer agent H3B-8800*
• Tavistock Life Sciences and Boxer Capital on acquiring PPAR Agonist-related assets*
• Ultragenyx on selling a priority review voucher to Novartis for US$130 million*
• Cellular Biomedicine Group on its licenses with NIH and Augusta University*
• La Jolla Pharmaceutical Company on its exclusive licenses with Vanderbilt University, the Indiana University Research and Technology Corporation, and the University of Alabama at Birmingham*
• Kirkbi Invest on acquiring a majority stake in Enerparc*
• MGM in its US$1.06 billion acquisition of Hard Rock Rocksino and in its US$850M asset acquisition of Empire City Casino*
• A Chinese consortium led by AGIC Capital on acquiring The Ritedose Corp from Olympus Partners, valued between US$600 million to US$800 million*
• Catch Surf on trademark and copyright licenses with Jordan Outdoor and True Axis*
• JamesSuckling.com on a web content licensing agreement to CellarTracker*
• Cogent Biosciences, Heron Therapeutics, Ginkgo Bioworks, Dianthus Therapeutics, Apogee Therapeutics, Rain Therapeutics, Eureka Therapeutics, Exelixis, Zivo Bioscience, Odonate Therapeutics, Omron Healthcare, OncoClinicas, Nanotics, and other clients with various license agreements, manufacturing and supply agreements, services arrangements, and other commercial agreements*

*Matter handled prior to joining Latham